SCHEMBL7181868

SCHEMBL7181868

CC(C)COc1cc(OCC(C)C)c(PC(=O)c2c(Cl)cccc2Cl)c(OCC(C)C)c1.[LiH]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOS P01100 2/20 0.40
JUN P05412 2/20 0.40
PTGER1 P34995 5/20 0.39
TBXA2R P21731 1/20 0.37
PPARG P37231 1/20 0.37
PTGER3 P43115 1/20 0.37
KMT2A Q03164 3/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HTR1D P28221 2/20 0.36
MEN1 O00255 2/20 0.36
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NR1H4 Q96RI1 2/20 0.36
SIRT2 Q8IXJ6 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189068 0.94 PTGER1 (0.38) FOSJUNPTGER1TBXA2RPPARG
SCHEMBL7175199 0.94 FOS (0.37) FOSJUNPTGER1MAPTHTR1D
SCHEMBL7179778 0.88 FOS (0.40) FOSJUNPTGER1KMT2AALDH1A1
SCHEMBL7189328 0.86 FOS (0.39) FOSJUNMAPTSIRT2NFKB1
SCHEMBL7177474 0.85 HTT (0.40) TDP1NR1H4TP53
SCHEMBL7182327 0.85 FOS (0.41) FOSJUNPTGER1KMT2AALDH1A1
SCHEMBL7180750 0.83 FOS (0.38) FOSJUNNR1H4SIRT2
SCHEMBL7180409 0.83 ELANE (0.47) ALDH1A1MAPTL3MBTL1NFKB1NFKB2
Lithium SCHEMBL7182340 0.83 FOS (0.39) FOSJUNPTGER1KMT2AALDH1A1
SCHEMBL7189839 0.82 ALDH1A1 (0.44) ALDH1A1TSHRTDP1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 FOS 2702/4885JUN 4136/4885PTGER1 3015/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 FOS 2549/4885JUN 3781/4885PTGER1 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.